E-cigarettes: An aid in smoking cessation, or a new health hazard?

Therapeutic Advances in Respiratory Disease

Volumn 12, Issue , 2018, Pages 1-20

  Farsalinos, Konstantinos ^a,b,c  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Electronic cigarettes; Nicotine; Public health; Smoking; Tobacco

Indexed keywords

CHEMICAL ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; ELECTRONIC CIGARETTE; EXPOSURE; HEALTH HAZARD; HEALTH IMPACT ASSESSMENT; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; RISK REDUCTION; SAFETY; SMOKING; SMOKING CESSATION; TOBACCO USE; TOXICOLOGY; ADOLESCENT; ADOLESCENT BEHAVIOR; ANIMAL; INHALATIONAL DRUG ADMINISTRATION; PROCEDURES; PRODUCT SAFETY; PSYCHOLOGY; RISK ASSESSMENT; SMOKING PREVENTION; VAPING;

NICOTINE; NICOTINIC AGENT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADOLESCENT BEHAVIOR; ANIMALS; CONSUMER PRODUCT SAFETY; ELECTRONIC NICOTINE DELIVERY SYSTEMS; HUMANS; NICOTINE; NICOTINIC AGONISTS; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION; SMOKING PREVENTION; TOBACCO USE CESSATION DEVICES; VAPING;

EID: 85045190314     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465817744960     Document Type: Review

References (208)

1. World Health Organization Global Health Observatory (GHO) data. World Health Statistics data visualizations dashboard. Tobacco smoking, http://apps.who.int/gho/data/node.sdg.3-a-viz?lang=en (accessed 21 November 2017).
2. U.S. Department of Health and Human Services. The health consequences of smoking: 50 years of progress. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, www.ncbi.nlm. nih.gov/books/NBK179276/ (2014, accessed 22 July 2017).
3. European Commission. Eurobarometer 429. Attitudes of Europeans towards tobacco and electronic cigarettes, http://ec.europa.eu/public_ opinion/archives/ebs/ebs_429_en.pdf (2014, accessed July 22 2017).
4. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11: CD000146.
5. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135–144.
6. Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329.
7. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6: 300.
8. Suissa K, Larivière J, Eisenberg MJ, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017; 10: pii: e002458.
9. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009; 338: b1024.
10. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009; 49: 57–71.
11. Caggiula AR, Donny EC, Chaudhri N, et al. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav 2002; 77: 683–687.
12. Bevins RA and Palmatier MI. Extending the role of associative learning processes in nicotine addiction. Behav Cogn Neurosci Rev 2004; 3: 143–158.
13. Niaura R. Cognitive social learning and related perspectives on drug craving. Addiction 2000; 95(Suppl. 2): S155–S163.
14. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2009; 121: 221–229.
15. Casella G, Caponnetto P and Polosa R. Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis 2010; 1: 95–106.
16. Farsalinos KE, Poulas K, Voudris V, et al. Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. Addiction 2016; 111: 2032–2040.
17. Edwards SA, Bondy SJ, Callaghan RC, et al. Prevalence of unassisted quit attempts in population-based studies: a systematic review of the literature. Addict Behav 2014; 39: 512–519.
18. Ritter A and Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug Alcohol Rev 2006; 25: 611–624.
19. Logan DE and Marlatt GA. Harm reduction therapy: a practice-friendly review of research. J Clin Psychol 2010; 66: 201–214.
20. Wilson DP, Donald B, Shattock AJ, et al. The cost-effectiveness of harm reduction. Int J Drug Policy 2015; 26(Suppl. 1): S5–S11.
21. Russell MA. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. Br Med J 1976; 1: 1430–1433.
22. Russell MAH, Jarvis MJ and Feyerabend C. A new age for snuff? Lancet 1980; 1: 474–475.
23. Kirkland LR. The nonsmoking uses of tobacco. New Engl J Med 1980; 303: 165.
24. Ramström L and Wikmans T. Mortality attributable to tobacco among men in Sweden and other European countries: an analysis of data in a WHO report. Tob Induc Dis 2014; 12: 14.
25. Gray NJ and Henningfield JE. A long-term view of harm reduction. Nicotine Tob Res 2004; 6: 759–764.
26. Sumner W II. Permissive nicotine regulation as a complement to traditional tobacco control. BMC Public Health 2005; 5: 18.
27. Bates C, Fagerström K, Jarvis MJ, et al. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control 2003; 12: 360– 367.
28. Kozlowski LT and Abrams DB. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction. BMC Public Health 2016; 16: 432.
29. Giovenco DP, Lewis MJ and Delnevo CD. Factors associated with e-cigarette use: a national population survey of current and former smokers. Am J Prev Med 2014; 47: 476–480.
30. Regan AK, Promoff G, Dube SR, et al. Electronic nicotine delivery systems: adult use and awareness of the ‘e-cigarette’ in the USA. Tob Control 2013; 22: 19–23.
31. Tan AS and Bigman CA. E-cigarette awareness and perceived harmfulness: prevalence and associations with smoking-cessation outcomes. Am J Prev Med 2014; 47: 141–149.
32. Adkison SE, O’Connor RJ, Bansal-Travers M, et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med 2013; 44: 207–215.
33. Gallus S, Lugo A, Pacifici R, et al. E-cigarette awareness, use, and harm perceptions in Italy: a national representative survey. Nicotine Tob Res 2014; 16: 1541–1548.
34. Brown J, West R, Beard E, et al. Prevalence and characteristics of e-cigarette users in Great Britain: findings from a general population survey of smokers. Addict Behav 2014; 39: 1120–1125.
35. McNeill A, Etter JF, Farsalinos K, et al. A critique of a World Health Organization-commissioned report and associated paper on electronic cigarettes. Addiction 2014; 109: 2128–2134.
36. Etter JF. Should electronic cigarettes be as freely available as tobacco? Yes. BMJ 2013; 346: f3845.
37. Middlekauff HR. Counterpoint: does the risk of electronic cigarettes exceed potential benefits? No. Chest 2015; 148: 582–584.
38. Schraufnagel DE, Blasi F, Drummond MB, et al.; Forum of International Respiratory Societies. Electronic cigarettes: a position statement of the forum of international respiratory societies. Am J Respir Crit Care Med 2014; 190: 611–618.
39. Chapman S. Should electronic cigarettes be as freely available as tobacco cigarettes? No. BMJ 2013; 346: f3840.
40. Avdalovic MV and Murin S. Point: does the risk of electronic cigarettes exceed potential benefits? Yes. Chest 2015; 148: 580–582.
41. Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043–1047.
42. Fifth Joint Task Force of the European Society of Cardiology. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012; 19: 585–667.
43. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005; 294: 1255–1259.
44. Mattson ME, Pollack ES and Cullen JW. What are the odds that smoking will kill you? Am J Public Health 1987; 77: 425–431.
45. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(Suppl. 5): e1S–e29S.
46. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497–1505.
47. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381–390.
48. Critchley J and Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; 1: CD003041.
49. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160: 939–944.
50. Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013; 61: 524–532.
51. Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality: a 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56: 702–706.
52. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368: 647–658.
53. Liu Y, Pleasants RA, Croft JB, et al. Smoking duration, respiratory symptoms, and COPD in adults aged ⩾45 years with a smoking history. Int J Chron Obstruct Pulmon Dis 2015; 10: 1409–1416.
54. Mucha L, Stephenson J, Morandi N, et al. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med 2006; 3: 279–291.
55. Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J 2005; 25: 1011–1017.
56. Godtfredsen NS, Prescott E and Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294: 1505–1510.
57. Pisinger C and Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine Tob Res 2007; 9: 631–646.
58. Hammond D. Smoking behaviour among young adults: beyond youth prevention. Tob Control 2005; 14: 181–185.
59. Wilkinson AV, Schabath MB, Prokhorov AV, et al. Age-related differences in factors associated with smoking initiation. Cancer Causes Control 2007; 18: 635–644.
60. Khuder SA, Dayal HH and Mutgi AB. Age at smoking onset and its effect on smoking cessation. Addict Behav 1999; 24: 673–677.
61. Everett SA, Warren CW, Sharp D, et al. Initiation of cigarette smoking and subsequent smoking behavior among US high school students. Prev Med 1999; 29: 327–333.
62. Fernandez E, Schiaffino A, La Vecchia C, et al. Age at starting smoking and number of cigarettes smoked in Catalonia, Spain. Prev Med 1999; 28: 361–366.
63. Hwang JH and Park SW. Age at smoking initiation and subsequent smoking among Korean adolescent smokers. J Prev Med Public Health 2014; 47: 266–272.
64. Ramström L, Borland R and Wikmans T. Patterns of smoking and snus use in Sweden: implications for public health. Int J Environ Res Public Health 2016; 13: pii: E1110.
65. Talhout R, Schulz T, Florek E, et al. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health 2011; 8: 613–628.
66. Borgerding M and Klus H. Analysis of complex mixtures: cigarette smoke. Exp Toxicol Pathol 2005; 57: 43–73.
67. Thielen A, Klus H and Muller L. Tobacco smoke: unraveling a controversial subject. Exp Toxicol Pathol 2008; 60: 141–156.
68. Rom O, Avezov K, Aizenbud D, et al. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol 2013; 187: 5–10.
69. Rahman I and MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol 1999; 277: L1067–L1088.
70. Bowler RP, Barnes PJ and Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. COPD 2004; 1: 255–277.
71. Hopkins JM and Evans HJ. Cigarette smoke-induced DNA damage and lung cancer risks. Nature 1980; 283: 388–390.
72. Wiencke JK, Thurston SW, Kelsey KT, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst 1999; 91: 614–619.
73. Chortyk OT and Schlotzhauer WS. Studies on the pyrogenesis of tobacco smoke constituents (a review). Beitr Tabakforsch 1973; 7: 165–178.
74. Rodgman A and Perfetti TA. The composition of cigarette smoke: a catalogue of the polycyclic aromatic hydrocarbons. Beitr Tabakforsch Int 2006; 22: 13–69.
75. Hoffmann D and Hoffmann I. The changing cigarette, 1950–1995. J Toxicol Environ Health 1997; 50: 307–364.
76. Andersen RA and Kemp TR. Accumulation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridy)-1-butanone in alkaloid genotypes of burley tobacco during postharvest processing: comparisons with N′-nitrosonornicotine and probable nitrosamine precursors. Cancer Res 1985; 45: 5287–5293.
77. Fischer S, Spiegelhalder B and Preussmann R. Preformed tobacco-specific nitrosamines in tobacco: role of nitrate and influence of tobacco type. Carcinogenesis 1989; 10: 1511–1517.
78. Guerin MR. Formation and physiochemical nature of sidestream smoke. In: O’Neill IK, Brunnemann KD, Dodet B, et al. (eds) Environmental carcinogens: methods of analysis and exposure measurement. Volume 9 – passive smoking. Lyon: International Agency for Research on Cancer; IARC Scientific Publications, 1987; pp.11–23.
79. Wurtz A. Mémoire sur les glycols ou alcools diatomiques. Ann Chim Phys 1859; 55: 400– 478.
80. FDA. Generally recognized as safe. 1982; 21 CFR 184.1666, www.gpo.gov/fdsys/pkg/CFR-2000-title21-vol3/pdf/CFR-2000-title21-vol3-sec184-1666.pdf (1982, accessed 3 August 2017).
81. DHHS/NTP-CERHR. NTP-CERHR monograph on the potential human reproductive and developmental effects of propylene glycol. March 2004. NIH Pub No. 04-4482, https://ntp.niehs.nih.gov/ntp/ohat/egpg/propylene/pg_monograph.pdf (accessed 29 July 2017).
82. Wang T, Noonberg S, Steigerwalt R, et al. Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med 2007; 20: 417–428.
83. Niven R, Lynch M, Moutvic R, et al. Safety and toxicology of cyclosporine in propylene glycol after 9-month aerosol exposure to beagle dogs. J Aerosol Med Pulm Drug Deliv 2011; 24: 205–212.
84. Farsalinos KE. Review of compounds of regulatory concern. In: Farsalinos KE, Gillman IG, Hecht S, et al. (eds) Analytical assessment of e-cigarettes: from contents to chemical and particle exposure profiles (emerging issues in analytical chemistry). Amsterdam: Elsevier, 2016.
85. Henle W and Zellat J. Effect of propylene glycol aerosol on air-borne virus of influenza. Proc Soc Exper Biol Med 1941; 48: 544.
86. Robertson OH, Loosli CG, Puck TT, et al. The protection of mice against infection with air-borne influenza virus by means of propylene glycol vapor. Science 1941; 94: 612–613.
87. Robertson OH, Loosli CG, Puck TT, et al. Tests for the chronic toxicity of propylene glycol and triethylene glycol on monkeys and rats by vapor inhalation and oral administration. J Pharmacol Exp Ther 1947; 91: 52–76.
88. Suber RL, Deskin R, Nikiforov I, et al. Subchronic nose-only inhalation study of propylene glycol in Sprague-Dawley rats. Food Chem Toxicol 1989; 27: 573–583.
89. Wieslander G, Norbäck D and Lindgren T. Experimental exposure to propylene glycol mist in aviation emergency training: acute ocular and respiratory effects. Occup Environ Med 2001; 58: 649–655.
90. Kanwal R, Kullman G, Piacitelli C, et al. Evaluation of flavorings-related lung disease risk at six microwave popcorn plants. J Occup Environ Med 2006; 48: 149–157.
91. Kreiss K, Gomaa A, Kullman G, et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med 2002; 347: 330–338.
92. National Institute for Occupational Safety and Health. Criteria for a recommended standard: occupational exposure to diacetyl and 2,3-pentanedione, www.cdc.gov/ niosh/docket/archive/pdfs/NIOSH-245/ DraftDiacetylCriteriaDocument081211.pdf (2011, accessed 2 August 2017).
93. Farsalinos KE, Kistler KA, Gillman G, et al. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. Nicotine Tob Res 2015; 17: 168–174.
94. Pierce JS, Abelmann A, Spicer LJ, et al. Diacetyl and 2,3-pentanedione exposures associated with cigarette smoking: implications for risk assessment of food and flavoring workers. Crit Rev Toxicol 2014; 44: 420–435.
95. Farsalinos KE, Gillman G, Poulas K, et al. Tobacco-specific nitrosamines in electronic cigarettes: comparison between liquid and aerosol levels. Int J Environ Res Public Health 2015; 12: 9046–9053.
96. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014; 23: 133–139.
97. Varlet V, Farsalinos K, Augsburger M, et al. Toxicity assessment of refill liquids for electronic cigarettes. Int J Environ Res Public Health 2015; 12: 4796–4815.
98. Margham J, McAdam K, Forster M, et al. Chemical composition of aerosol from an e-cigarette: a quantitative comparison with cigarette smoke. Chem Res Toxicol 2016; 29: 1662–1678.
99. Farsalinos KE, Gillman IG, Melvin MS, et al. Nicotine levels and presence of selected tobacco-derived toxins in tobacco flavoured electronic cigarette refill liquids. Int J Environ Res Public Health 2015; 12: 3439–3452.
100. Tayyarah R and Long GA. Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. Regul Toxicol Pharmacol 2014; 70: 704–710.
101. Farsalinos KE, Voudris V and Poulas K. E-cigarettes generate high levels of aldehydes only in ‘dry puff’ conditions. Addiction 2015; 110: 1352–1356.
102. Gillman IG, Kistler KA, Stewart EW, et al. Effect of variable power levels on the yield of total aerosol mass and formation of aldehydes in e-cigarette aerosols. Regul Toxicol Pharmacol 2016; 75: 58–65.
103. Geiss O, Bianchi I and Barrero-Moreno J. Correlation of volatile carbonyl yields emitted by e-cigarettes with the temperature of the heating coil and the perceived sensorial quality of the generated vapours. Int J Hyg Environ Health 2016; 219: 268–277.
104. Jensen RP, Luo W, Pankow JF, et al. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med 2015; 372: 392–394.
105. Sleiman M, Logue JM and Montesinos VN. Emissions from electronic cigarettes: key parameters affecting the release of harmful chemicals. Environ Sci Technol 2016; 50: 9644–9651.
106. Khlystov A and Samburova V. Flavoring compounds dominate toxic aldehyde production during e-cigarette vaping. Environ Sci Technol 2016; 50: 13080–13085.
107. Bekki K, Uchiyama S, Ohta K, et al. Carbonyl compounds generated from electronic cigarettes. Int J Environ Res Public Health 2014; 11: 11192–11200.
108. Farsalinos KE, Romagna G, Tsiapras D, et al. Evaluation of electronic cigarette use (vaping) topography and estimation of liquid consumption: implications for research protocol standards definition and for public health authorities’ regulation. Int J Environ Res Public Health 2013; 10: 2500–2514.
109. Farsalinos KE, Romagna G, Allifranchini E, et al. Comparison of the cytotoxic potential of cigarette smoke and electronic cigarette vapour extract on cultured myocardial cells. Int J Environ Res Public Health 2013; 10: 5146–5162.
110. Farsalinos KE, Voudris V, Spyrou A, et al. E-cigarettes emit very high formaldehyde levels only in conditions that are aversive to users: a replication study under verified realistic use conditions. Food Chem Toxicol 2017; 109: 90–94.
111. Williams M, Villarreal A, Bozhilov K, et al. Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. PLoS One 2013; 8: e57987.
112. Williams M, To A, Bozhilov K, et al. Strategies to reduce tin and other metals in electronic cigarette aerosol. PLoS One 2015; 10: e0138933.
113. Farsalinos KE, Voudris V and Poulas K. Are metals emitted from electronic cigarettes a reason for health concern? A risk-assessment analysis of currently available literature. Int J Environ Res Public Health 2015; 12: 5215–5232.
114. Fernández E, Ballbè M, Sureda X, et al. Particulate matter from electronic cigarettes and conventional cigarettes: a systematic review and observational study. Curr Environ Health Rep 2015; 2: 423–429.
115. Ruprecht AA, De Marco C, Pozzi P, et al. Comparison between particulate matter and ultrafine particle emission by electronic and normal cigarettes in real-life conditions. Tumori 2014; 100: e24–e27.
116. Zhang Y, Sumner W and Chen DR. In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns. Nicotine Tob Res 2013; 15: 501–508.
117. Borzelleca JF. Paracelsus: herald of modern toxicology. Toxicol Sci 2000; 53: 2–4.
118. Canistro D, Vivarelli F, Cirillo S, et al. E-cigarettes induce toxicological effects that can raise the cancer risk. Sci Rep 2017; 7: 2028.
119. Wu Q, Jiang D, Minor M, et al. Electronic cigarette liquid increases inflammation and virus infection in primary human airway epithelial cells. PLoS One 2014; 9: e108342.
120. Higham A, Rattray NJ and Dewhurst JA. Electronic cigarette exposure triggers neutrophil inflammatory responses. Respir Res 2016; 17: 56.
121. Shen Y, Wolkowicz MJ, Kotova T, et al. Transcriptome sequencing reveals e-cigarette vapor and mainstream-smoke from tobacco cigarettes activate different gene expression profiles in human bronchial epithelial cells. Sci Rep 2016; 6: 23984.
122. Taylor M, Jaunky T, Hewitt K, et al. A comparative assessment of e-cigarette aerosols and cigarette smoke on in vitro endothelial cell migration. Toxicol Lett 2017; 277: 123–128.
123. Taylor M, Carr T, Oke O, et al. E-cigarette aerosols induce lower oxidative stress in vitro when compared to tobacco smoke. Toxicol Mech Methods 2016; 26: 465–476.
124. Carnevale R, Sciarretta S, Violi F, et al. Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function. Chest 2016; 150: 606–612.
125. Vlachopoulos C, Ioakeimidis N, Abdelrasoul M, et al. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. J Am Coll Cardiol 2016; 67: 2802– 2803.
126. Adamopoulos D, Argacha JF, Gujic M, et al. Acute effects of nicotine on arterial stiffness and wave reflection in healthy young non-smokers. Clin Exp Pharmacol Physiol 2009; 36: 784–789.
127. Mahmud A and Feely J. Acute effect of caffeine on arterial stiffness and aortic pressure waveform. Hypertension 2001; 38: 227–231.
128. Vlachopoulos C, Panagiotakos D, Ioakeimidis N, et al. Chronic coffee consumption has a detrimental effect on aortic stiffness and wave reflections. Am J Clin Nutr 2005; 81: 1307– 1312.
129. Mutter AF, Cooke AB, Saleh O, et al. A systematic review on the effect of acute aerobic exercise on arterial stiffness reveals a differential response in the upper and lower arterial segments. Hypertens Res 2017; 40: 146–172.
130. Moheimani RS, Bhetraratana M and Yin F. Increased cardiac sympathetic activity and oxidative stress in habitual electronic cigarette users: implications for cardiovascular risk. JAMA Cardiol 2017; 2: 278–284.
131. Polosa R, Morjaria JB, Caponnetto P, et al. Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. Discov Med 2016; 21: 99–108.
132. Farsalinos K, Cibella F, Caponnetto P, et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Intern Emerg Med 2016; 11: 85–94.
133. Polosa R, Morjaria JB, Caponnetto P, et al. Blood pressure control in smokers with arterial hypertension who switched to electronic cigarettes. Int J Environ Res Public Health 2016; 13: pii: E1123.
134. Hecht SS, Carmella SG, Kotandeniya D, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res 2015; 17: 704–709.
135. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med 2017; 166: 390–400.
136. Farsalinos KE and Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 2014; 5: 67–86.
137. Grana R, Benowitz N and Glantz SA. E-cigarettes: a scientific review. Circulation 2014; 129: 1972–1986.
138. Glasser AM, Collins L and Pearson JL. Overview of electronic nicotine delivery systems: a systematic review. Am J Prev Med 2017; 52: e33–e66.
139. Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tob Control. Epub ahead of print 4 August 2017. DOI: 10.1136/tobaccocontrol-2017-053808.
140. Editorial (no authors listed). E-cigarettes: Public Health England’s evidence-based confusion. Lancet 2015; 386: 829.
141. Gornall J. Public Health England’s troubled trail. BMJ 2015; 351: h5826.
142. McKee M and Capewell S. Evidence about electronic cigarettes: a foundation built on rock or sand? BMJ 2015; 351: h4863.
143. McNeill A, Brose LS, Calder R, et al. E-cigarettes: the need for clear communication on relative risks. Lancet 2015; 386: 1237.
144. Farsalinos KE, Romagna G, Tsiapras D, et al. Impact of flavour variability on electronic cigarette use experience: an internet survey. Int J Environ Res Public Health 2013; 10: 7272– 7282.
145. Dawkins L, Turner J, Roberts A, et al. ‘Vaping’ profiles and preferences: an online survey of electronic cigarette users. Addiction 2013; 108: 1115–1125.
146. Farsalinos KE, Romagna G, Tsiapras D, et al. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int J Environ Res Public Health 2014; 11: 4356–4373.
147. Gucht DV, Adriaens K and Baeyens F. Online vape shop customers who use e-cigarettes report abstinence from smoking and improved quality of life, but a substantial minority still have vaping-related health concerns. Int J Environ Res Public Health 2017; 14: pii: E798.
148. Tackett AP, Lechner WV, Meier E, et al. Biochemically verified smoking cessation and vaping beliefs among vape store customers. Addiction 2015; 110: 868–874.
149. Caponnetto P, Campagna D, Cibella F, et al. Efficiency and safety of an electronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One 2013; 8: e66317.
150. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382: 1629–1637.
151. Adriaens K, Van Gucht D, Declerck P, et al. Effectiveness of the electronic cigarette: an eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. Int J Environ Res Public Health 2014; 11: 11220– 11248.
152. Brose LS, Hitchman SC, Brown J, et al. Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction 2015; 110: 1160–1168.
153. Al-Delaimy WK, Myers MG, Leas EC, et al. E-cigarette use in the past and quitting behavior in the future: a population-based study. Am J Public Health 2015; 105: 1213–1219.
154. Biener L and Hargraves JL. A longitudinal study of electronic cigarette use among a population-based sample of adult smokers: association with smoking cessation and motivation to quit. Nicotine Tob Res 2015; 17: 127–133.
155. Vickerman KA, Carpenter KM, Altman T, et al. Use of electronic cigarettes among state tobacco cessation quitline callers. Nicotine Tob Res 2013; 15: 1787–1793.
156. Manzoli L, Flacco ME, Fiore M, et al. Electronic cigarettes efficacy and safety at 12 months: cohort study. PLoS One 2015; 10: e0129443.
157. Borderud SP, Li Y, Burkhalter JE, et al. Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer 2014; 120: 3527–3535.
158. McRobbie H, Bullen C, Hartmann-Boyce J, et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014; 12: CD010216.
159. Hartmann-Boyce J, McRobbie H, Bullen C, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2016; 9: CD010216.
160. Rahman MA, Hann N, Wilson A, et al. E-cigarettes and smoking cessation: evidence from a systematic review and meta-analysis. PLoS One 2015; 10: e0122544.
161. Kalkhoran S and Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 2016; 4: 116–128.
162. El Dib R, Suzumura EA, Akl EA, et al. Electronic nicotine delivery systems and/or electronic non-nicotine delivery systems for tobacco smoking cessation or reduction: a systematic review and meta-analysis. BMJ Open 2017; 7: e012680.
163. Amato MS, Boyle RG and Levy D. How to define e-cigarette prevalence? Finding clues in the use frequency distribution. Tob Control 2016; 25: e24–e29.
164. Levy DT, Yuan Z, Luo Y, et al. The relationship of e-cigarette use to cigarette quit attempts and cessation: insights from a large, nationally representative U.S. survey. Nicotine Tob Res. Epub ahead of print 31 August 2017. DOI: 10.1093/ntr/ntx166.
165. Frieden TR. Evidence for health decision making: beyond randomized, controlled trials. N Engl J Med 2017; 377: 465–475.
166. Farsalinos KE and Stimson GV. Is there any legal and scientific basis for classifying electronic cigarettes as medications? Int J Drug Policy 2014; 25: 340–345.
167. Edwards SA, Bondy SJ, Callaghan RC, et al. Prevalence of unassisted quit attempts in population-based studies: a systematic review of the literature. Addict Behav 2014; 39: 512–519.
168. Action on Smoking and Health UK. Use of electronic cigarettes (vapourisers) among adults in Great Britain, http://ash.org.uk/information-and-resources/fact-sheets/use-of-e-cigarettes-among-adults-in-great-britain-2017/(accessed 3 August 2017).
169. Farsalinos KE, Poulas K, Voudris V, et al. Prevalence and correlates of current daily use of electronic cigarettes in the European Union: analysis of the 2014 Eurobarometer survey. Intern Emerg Med. Epub ahead of print 4 March 2017. DOI: 10.1007/s11739-017-1643-1647.
170. Brown J, Beard E, Kotz D, et al. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 2014; 109: 1531–1540.
171. Beard E, West R, Michie S, et al. Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends. BMJ 2016; 354: i4645.
172. Maziak W and Ben Taleb Z. Eurobarometer survey and e-cigarettes: unsubstantiated claims. Addiction 2017; 112: 545.
173. Schoenborn CA and Gindi RM. Electronic cigarette use among adults: United States, 2014. NCHS Data Brief 2015; 217: 1–8.
174. Delnevo CD, Giovenco DP, Steinberg MB, et al. Patterns of electronic cigarette use among adults in the United States. Nicotine Tob Res 2016; 18: 715–719.
175. Coleman BN, Rostron B, Johnson SE, et al. Electronic cigarette use among US adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013–2014. Tob Control. Epub ahead of print 17 June 2017. DOI: 10.1136/tobaccocontrol-2016-053462.
176. Kinnunen JM, Ollila H, El-Amin Sel-T, et al. Awareness and determinants of electronic cigarette use among Finnish adolescents in 2013: a population-based study. Tob Control 2015; 24: e264–e270.
177. Gallus S, Lugo A, Pacifici R, et al. E-cigarette awareness, use, and harm perceptions in Italy: a national representative survey. Nicotine Tob Res 2014; 16: 1541–1548.
178. Andler R, Guignard R, Wilquin JL, et al. Electronic cigarette use in France in 2014. Int J Public Health 2016; 61: 159–165.
179. Shiplo S, Czoli CD and Hammond D. E-cigarette use in Canada: prevalence and patterns of use in a regulated market. BMJ Open 2015; 5: e007971.
180. Reid JL, Rynard VL, Czoli CD, et al. Who is using e-cigarettes in Canada? Nationally representative data on the prevalence of e-cigarette use among Canadians. Prev Med 2015; 81: 180–183.
181. Li J, Newcombe R and Walton D. The prevalence, correlates and reasons for using electronic cigarettes among New Zealand adults. Addict Behav 2015; 45: 245–251.
182. Giovenco DP, Lewis MJ and Delnevo CD. Factors associated with e-cigarette use: a national population survey of current and former smokers. Am J Prev Med 2014; 47: 476–480.
183. Kasza KA, Ambrose BK, Conway KP, et al. Tobacco-product use by adults and youths in the United States in 2013 and 2014. N Engl J Med 2017; 376: 342–353.
184. McRobbie H, Phillips A, Goniewicz ML, et al. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. CancePrev Res (Phila) 2015; 8: 873–878.
185. D’Ruiz CD, Graff DW and Robinson E. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health 2016; 16: 543.
186. Zhuang YL, Cummins SE, Sun JY, et al. Long-term e-cigarette use and smoking cessation: a longitudinal study with US population. Tob Control 2016; 25(Suppl. 1): i90–i95.
187. U.S. Department of Health and Human Services. E-cigarette use among youth and young adults: a report of the Surgeon General—executive summary. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016.
188. Arrazola RA, Singh T, Corey CG, et al.; Centers for Disease Control and Prevention (CDC). Tobacco use among middle and high school students: United States, 2011–2014. Morb Mortal Wkly Rep 2015; 64: 381–385.
189. Singh T, Arrazola RA, Corey CG, et al. Tobacco use among middle and high school students: United States, 2011–2015. Morb Mortal Wkly Rep 2016; 65: 361–367.
190. Johnston LD, O’Malley PM, Miech RA, et al. Monitoring the future national survey results on drug use, 1975–2014: overview, key findings on adolescent drug use. Ann Arbor, MI: Institute for Social Research, University of Michigan, www. monitoringthefuture.org/pubs/monographs/ mtf-overview2014.pdf (2015, accessed 2 August 2017).
191. Johnston LD, O’Malley PM, Miech RA, et al. Monitoring the future national survey results on drug use, 1975–2015: overview, key findings on adolescent drug use. Ann Arbor, MI: Institute for Social Research, University of Michigan, www. monitoringthefuture.org/pubs/monographs/ mtf-overview2015.pdf (2016, accessed 2 August 2017).
192. Villanti AC, Pearson JL, Glasser AM, et al. Frequency of youth e-cigarette and tobacco use patterns in the U.S.: measurement precision is critical to inform public health. Nicotine Tob Res. Epub ahead of print 24 December 2016. DOI: 10.1093/ntr/ntw388.r
193. Warner KE. Frequency of e-cigarette use and cigarette smoking by American Students in 2014. Am J Prev Med 2016; 51: 179–184.
194. Miech R, Patrick ME, O’Malley PM, et al. What are kids vaping? Results from a national survey of US adolescents. Tob Control 2017; 26: 386–391.
195. Moore G, Hewitt G, Evans J, et al. Electronic-cigarette use among young people in Wales: evidence from two cross-sectional surveys. BMJ Open 2015; 5: e007072.
196. Eastwood B, Dockrell MJ, Arnott D, et al. Electronic cigarette use in young people in Great Britain 2013–2014. Public Health 2015; 129: 1150–1156.
197. Bauld L, MacKintosh AM, Eastwood B, et al. Young people’s use of e-cigarettes across the United Kingdom: findings from five surveys 2015–2017. Int J Environ Res Public Health 2017; 14: pii: E973.
198. Polosa R, Russell C, Nitzkin J, et al. A critique of the US Surgeon General’s conclusions regarding e-cigarette use among youth and young adults in the United States of America. Harm Reduct J 2017; 14: 61.
199. Jamal A, Gentzke A, Hu SS, et al. Tobacco use among middle and high school students: United States, 2011–2016. Morb Mortal Wkly Rep 2017; 66: 597–603.
200. Johnston LD, O’Malley PM, Miech RA, et al. Monitoring the future national survey results on drug use, 1975–2016: overview, key findings on adolescent drug use. Ann Arbor, MI: Institute for Social Research, University of Michigan, www. monitoringthefuture.org/pubs/monographs/ mtf-overview2016.pdf (2017, accessed 2 August 2017).
201. Leventhal AM, Strong DR, Kirkpatrick MG, et al. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. JAMA 2015; 314: 700–707.
202. Primack BA, Soneji S, Stoolmiller M, et al. Progression to traditional cigarette smoking after electronic cigarette use among USadolescents and young adults. JAMA Pediatr 2015; 169: 1018–1023.
203. Wills TA, Knight R, Sargent JD, et al. Longitudinal study of e-cigarette use and onset of cigarette smoking among high school students in Hawaii. Tob Control 2017; 26: 34–39.
204. Barrington-Trimis JL, Berhane K, Unger JB, et al. The e-cigarette social environment, e-cigarette use, and susceptibility to cigarette smoking. J Adolesc Health 2016; 59: 75–80.
205. Unger JB, Soto DW and Leventhal A. E-cigarette use and subsequent cigarette and marijuana use among Hispanic young adults. Drug Alcohol Depend 2016; 163: 261–264.
206. Soneji S, Barrington-Trimis JL, Wills TA, et al. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr 2017; 171: 788–797.
207. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300.
208. Niaura RS, Glynn TJ and Abrams DB. Youth experimentation with e-cigarettes: another interpretation of the data. JAMA 2014; 312: 641–642.